# Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

> **NCT06978439** · PHASE4 · RECRUITING · sponsor: **Children's Hospital of Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Kawasaki Disease
- Pilot Study
- Coronary Artery Aneurysm
- Rivaroxaban

## Interventions

- **DRUG:** Rivaroxaban (Xarelto)

## Key facts

- **NCT ID:** NCT06978439
- **Lead sponsor:** Children's Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-10
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978439, "Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06978439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*